Akari Therapeutics PLC (NASDAQ:AKTX) has been assigned a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has given a strong buy recommendation to the company.
Brokers have set a twelve-month consensus target price of $2.50 for the company and are anticipating that the company will post ($1.00) EPS for the current quarter, according to Zacks. Zacks has also assigned Akari Therapeutics an industry rank of 115 out of 265 based on the ratings given to related companies.
A number of research firms have commented on AKTX. ValuEngine raised Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Zacks Investment Research raised Akari Therapeutics from a “sell” rating to a “hold” rating and set a $5.00 target price on the stock in a report on Monday, November 13th. Canaccord Genuity reaffirmed a “buy” rating and issued a $15.00 target price on shares of Akari Therapeutics in a report on Friday, September 22nd. William Blair raised Akari Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, September 22nd. Finally, Chardan Capital reaffirmed a “neutral” rating on shares of Akari Therapeutics in a report on Sunday, September 17th.
Shares of Akari Therapeutics (AKTX) opened at $4.53 on Friday. The company has a market capitalization of $54.65, a PE ratio of -16.18 and a beta of -9.06. Akari Therapeutics has a twelve month low of $3.18 and a twelve month high of $22.20.
An institutional investor recently raised its position in Akari Therapeutics stock. Hikari Power Ltd increased its stake in Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 151,334 shares of the biopharmaceutical company’s stock after acquiring an additional 91,322 shares during the period. Hikari Power Ltd owned approximately 1.28% of Akari Therapeutics worth $929,000 as of its most recent SEC filing. Institutional investors own 20.95% of the company’s stock.
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.